Stay updated on ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial
Sign up to get notified when there's something new on the ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial page.

Latest updates to the ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe study has transitioned from a recruiting status to an active status, indicating it is currently ongoing. Additionally, the number of study locations has decreased from 22 to 17, and several principal investigators and their contact information have been removed.SummaryDifference17%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check37 days agoChange DetectedDifference0.2%
- Check44 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check51 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check58 days agoChange DetectedDifference0.3%
Stay in the know with updates to ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial page.